Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

• Status: Recruiting
• Trial end date: 2022-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing the cardiovascular risks in this patient population. Recently, some studies have shown that a drug typically used to improve glucose control (pioglitazone) may also reduce sympathetic nerve activity and improve blood vessel function.

The goal of this study is to determine whether a short-term treatment with pioglitazone can reduce sympathetic nerve impulses throughout the body in CKD patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Texas at Arlington
• Collaborator: University of Texas, Southwestern Medical Center at Dallas
• Treatments: Pioglitazone

Criteria

Inclusion Criteria:

• CKD patients classified as Stage 3 and 4 of National Kidney Foundation Classification with estimated glomerular filtration rate (GFR) between 15 and 59 mL/min/1.73 m2 according to the Modification of Diet in Renal Disease (MDRD) formula based on serum creatinine, age, gender, and race.

• Men and women 35 to 70 years of age

Exclusion Criteria:

• Allergy to Glitazones

• Myocardial infarction

• Heart failure

• Angina

• History of kidney stones

• Liver disease (abnormal liver enzymes)

• Anemia (hemoglobin <8 g/dl)

• Cancer with current treatment

• Previous organ transplantation

• Immunosuppressant therapy

• Human immunodeficiency virus infection

• Pregnancy or lactating

• Current tobacco use

• Dilantin and oral contraceptive usage due to potential drug interaction with glitazones

• Self-identified history of hypoglycemia